跳到正文
原文
PharmaTimes· John Pinching·· 2026-10-01AI 评分27

Novotech 拟收购 Agilex Biolabs

Novotech to acquire Agilex Biolabs

AI 导读

Novotech 已达成协议,将从 Healius 旗下子公司收购位于阿德莱德的 Agilex Biolabs。该交易旨在通过整合澳大利亚生物分析专业知识,增强 Novotech 在亚太地区的临床开发能力。交易完成尚需满足包括监管批准在内的常规条件。

正文

Deal adds bioanalytical expertise in Australia

Novotech has reached agreement to acquire Agilex Biolabs, a specialist bioanalytical laboratory headquartered in Adelaide, from a subsidiary of Healius. The company said the deal will strengthen its clinical development capabilities by adding Australian bioanalytical expertise to its existing laboratory network across Asia.

“Agilex has an outstanding scientific reputation. This acquisition enhances Novotech’s offering in Australia, bringing together bioanalytical science and research capabilities to deliver innovative and ground-breaking research. We look forward to welcoming the Agilex team,” said Dr Anand Tharmaratnam, Chief Executive Officer of Novotech.

He added: “This acquisition enhances Novotech’s offering in Australia, bringing together bioanalytical science and research capabilities to deliver innovative and ground-breaking research.”

“The sale provides customers and team members of Agilex Biolabs with the opportunity to join an established and global business in Novotech, which has expertise in providing services to major biotechnology and pharmaceutical customers” said Paul Anderson, Managing Director & CEO of Healius Limited.

He explained: “The sale provides customers and team members of Agilex Biolabs with the opportunity to join an established and global business in Novotech.”

The acquisition will allow Novotech to offer biotech and pharmaceutical sponsors more responsive R&D support in Australia, which remains one of the world’s most attractive destinations for early-phase clinical research. Completion of the transaction is subject to customary conditions, including regulatory clearances.

Novotech is a global full-service clinical research organisation with more than 30 offices across Asia-Pacific, North America and Europe. The company partners with over 5,000 trial sites and provides integrated clinical development services for biotech and small to mid-sized pharmaceutical companies.

Novotech is backed by TPG, Temasek and GIC.

来源:PharmaTimes · pharmatimes.com